Tag: GlobeNewswire

Company and President Frank Ingriselli Also Highlighted in Recent CNBC Interview

JAKARTA, INDONESIA AND DANVILLE, CA, Oct. 06, 2026 (GLOBE NEWSWIRE) — Indonesia Energy Corporation (NYSE American: INDO) (“IEC”), an oil and gas exploration and production company focused on Indonesia, today announced, that its President Frank Ingriselli led a delegation in early October to IEC’s Kruh Block in Sumatra, Indonesia to celebrate oil production from the recently drilled K-29 well.

The delegation also visited the nearby WK-5 well location, where site setup and rig assembly (using the same rig that drilled the K-29 well) are actively underway. Preparations are also ongoing for the anticipated spudding of the WK-5 well by the end of this month.

The WK-5 well is planned to be drilled to a depth of approximately 5,200 feet, significantly deeper than the K-29 well, which was drilled to approximately 3,400 feet. WK-5 is designed to test additional formations identified through IEC’s extensive 3-D seismic program, including a potential natural gas-bearing formation. K-29 and WK-5 are each located within IEC’s 63,000-acre Kruh Block on the island of Sumatra.

A video showing oil production from K-29 and the delegation’s visit to the WK-5 site can be viewed at the following link: https://www.youtube.com/watch?v=uW2igiI9p4U

In addition, IEC announced that Mr. Ingriselli and IEC were recently featured in a CNBC interview as part of a segment highlighting innovative microcap companies. The CNBC interview can be viewed here: https://youtu.be/uYdi3KfvFNs

These videos, along with an interview with Frank Ingriselli from the recent EnerCom conference, in Denver, Colorado are also available on IEC’s website at: https://ir.indo-energy.com

Mr. Ingriselli commented “I was extremely pleased to lead our delegation to the Kruh Block to celebrate production from K-29 and to visit the WK-5 location as we prepare to spud this exciting new well. WK-5 will be drilled significantly deeper than K-29 and is designed to test additional formations identified by our 3-D seismic program. We believe these formations have the potential to add significant value to IEC.

“With the drilling equipment and crews already mobilized at the Kruh Block, we are also taking advantage of this opportunity to conduct a hydraulic fracturing operation on K-29 with the goal of maximizing production. K-29 is currently producing with a jack-pump and dewatering, with production currently consisting of approximately 60% oil and a 40% water cut and separated into our storage tanks and is being combined with our other producing wells and sold to Pertamina, the Indonesian state oil and gas company.

“We are excited by the progress at Kruh and look forward to the upcoming drilling of WK-5 as we continue working to increase production and unlock the potential of our assets in Indonesia,” concluded Mr. Ingriselli.

About Indonesia Energy Corporation Limited

Indonesia Energy Corporation Limited (NYSE American: INDO) is a publicly traded energy company engaged in the acquisition and development of strategic, high growth energy projects in Indonesia. IEC’s principal assets are its Kruh Block (63,000 acres) located onshore on the Island of Sumatra in Indonesia and its Citarum Block (195,000 acres) located onshore on the Island of Java in Indonesia. IEC is headquartered in Jakarta, Indonesia and has a representative office in Danville, California. For more information on IEC, please visit www.indo-energy.com.

Cautionary Statement Regarding Forward-Looking Statements

All statements in this press release, the videos presented herein, and related statements of Indonesia Energy Corporation Limited (“IEC”) and its representatives and partners that are not based on historical fact are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 and the provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the “Acts”). In particular, the words “explore,” “could,” “estimates,” “seek,” “believes,” “hopes,” “understand,” “expects,” “intends,” “on-track”, “plans,” “anticipates,” “aim,” “goal,” “may” and similar conditional expressions related to the future are intended to identify forward-looking statements within the meaning of the Acts and are subject to the safe harbor created by the Acts. Any statements made in this news release, other than those of historical fact, about an action, event or development, are forward-looking statements. In this press release, forward-looking statements include, without limitation those related to the timing for, and results of, 2026 and other drilling and anticipated production activities at IEC’s Kruh Block as well as the price of oil and natural gas, which changes daily and could lower over time. While management has based any forward-looking statements contained herein on its current expectations, the information on which such expectations were based may change. These forward-looking statements rely on a number of assumptions concerning future events and are subject to a number of significant risks, uncertainties, and other factors, many of which are outside of the IEC’s control, that could cause actual results to materially and adversely differ from such statements. Such risks, uncertainties, and other factors include, but are not necessarily limited to, those set forth in the Risk Factors section of IEC’s annual report on Form 20-F for the fiscal year ended December 31, 2025, filed on April 29, 2026, and other filings with the Securities and Exchange Commission (SEC). Copies are of such documents are available on the SEC’s website, www.sec.gov and IEC’s website at https://ir.indo-energy.com/sec-filings/. IEC undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.

Company Contact:
Frank C. Ingriselli
President, Indonesia Energy Corporation Limited
Frank.Ingriselli@Indo-Energy.com

• Transaction expected to add approximately US$2.0m in Annual Recurring Revenue (ARR) and approximately US$900k in EBIT
• Established multi-location customer base that includes a Fortune 100 company
• Approximately 10,000+ end customers create possibly significant cross-selling opportunities for Locafy’s proprietary AEO and SEO products

PERTH, Australia, Oct. 06, 2026 (GLOBE NEWSWIRE) — Locafy Limited (Nasdaq: LCFY, LCFYW) (“Locafy” or the “Company”), a global SaaS technology company specializing in location-based Search Engine Optimization (SEO) and Answer Engine Optimization (AEO), today announced that it has entered into a definitive agreement to acquire the assets and customer base of Map Labs, a U.S.-based maps marketing software and services business, for total potential cash consideration of up to US$3.0 million, subject to the satisfaction of customary closing conditions. The Company believes the transaction, which is scheduled to close on or before December 31, 2026, is expected to materially increase Locafy’s revenue and operating profitability while accelerating its U.S. growth strategy.

Key Highlights

• Scale and profitability: Based on unaudited management estimates, Map Labs is expected to generate approximately US$2.0 million (A$2.84 million) in annual recurring revenue (ARR) and approximately US$900,000 (A$1.27 million) of Earnings Before Interest and Taxes (EBIT) in calendar year 2026, representing an approximate 45% EBIT margin and valuation of 2.2x EBIT.
• Performance-based consideration: The acquisition is structured as US$2.0 million payable upfront with an additional US$1.0 million contingent upon the acquired business achieving significant future revenue growth. US$500,000 is payable if Map Labs achieves greater than US$3.84 million of revenue during calendar year 2027 (approximately 92% growth compared to US$2.0 million), with a further US$500,000 payable if revenue exceeds US$4.76 million during calendar year 2028 (approximately 138% growth compared to US$2.0 million).
• Pathways to drive growth and margin expansion: Locafy will combine Map Labs’ established U.S. multi-location customer base and Maps marketing capabilities with Locafy’s SEO, AEO, citation, automation and AI-powered website technologies. The Company expects to drive cross-selling, automation-led efficiencies, and increased operating leverage across the combined customer base.
• The Company intends to fund the upfront consideration primarily through a debt facility. No Locafy securities will be issued as consideration in connection with the acquisition.

“We believe this is a transformational transaction for Locafy,” said Gavin Burnett, Chief Executive Officer of Locafy. “We believe Map Labs will add an established U.S. customer base and profitable operating platform that increases our scale. The transaction provides an attractive entry valuation, with US$1.0 million of the potential consideration tied to future revenue growth. This structure aligns a meaningful portion of the purchase price with performance while preserving substantial upside for Locafy.”

A Possible Profitable U.S. Platform with Upside

Founded in 2014, Map Labs helps multi-location businesses improve their visibility and customer acquisition across Google Search, Google Maps and Apple Maps.

Its software and services include Google Business Profile management, Local Pack optimization, Maps advertising, listing management, bulk profile management, performance reporting and location-level marketing strategy.

Map Labs serves customers across a range of industries, including restaurants, hospitality, healthcare, retail, fitness and professional services.

We believe the acquisition will provide Locafy with an established base of larger, multi-location U.S. customers and will expand the Company’s capabilities in Maps marketing and Google Business Profile management.

Opportunity to Increase Margins Through Automation

Locafy expects to begin integrating the acquired operations immediately after closing.

During the initial 90-day transition period, Locafy plans to introduce its automation technologies into selected Map Labs workflows with the objective of reducing manual processes, improving service delivery and increasing operating efficiency.

Jason Jackson, Chief Operating Officer of Locafy, said, “The operational fit between the two businesses is strong. We expect that our first priority will be a seamless transition for Map Labs customers. We intend to then apply Locafy’s automation and scalable delivery systems to Map Labs’ proven service model to reduce manual processes, increase capacity and improve operating leverage.”

Cross-Selling Creates Additional Revenue Opportunity

We believe the combination also creates opportunities to increase revenue from both businesses’ existing customer bases. Locafy intends to introduce Map Labs’ Google Business Profile management, Maps marketing and Local Pack capabilities to appropriate Locafy customers.

At the same time, Locafy plans to introduce its broader portfolio of citation services, Localizer solutions, AEO technologies and Proteus™ AI website generation platform to suitable Map Labs customers.

Liz Willits, Chief Marketing Officer of Locafy, said, “We believe this acquisition creates a broader and more complete customer proposition. We can introduce Maps marketing and Google Business Profile capabilities to Locafy customers while giving Map Labs customers access to our SEO, AEO, citation, and AI-powered website solutions.

“We believe the ability to cross-sell Locafy products into Map Labs’ established customer base is an important part of the growth opportunity. We believe it creates a pathway to increase revenue from existing customers without relying solely on new customer acquisition, while also providing additional value to those customers through a broader range of solutions.”

About Map Labs

Founded in 2014, Map Labs is a U.S.-based maps marketing software and services business that helps multi-location organizations manage and improve their presence across Google Search, Google Maps and Apple Maps.

Map Labs combines specialized strategy, software, Google Business Profile management, listing optimization and performance reporting to help businesses increase local visibility and convert search activity into customer actions.

For more information, visit www.maplabs.com.

About Locafy

Founded in 2009, Locafy (Nasdaq: LCFY, LCFYW) is on a mission to accelerate visibility and prominence for local, national and brand-focused businesses across online and AI search engines through proprietary SEO techniques, technologies and AI-driven automation.

For more information, please visit www.locafy.com.

Forward-Looking Statements

This press release contains “forward-looking statements” that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as “subject to”, “believe,” “anticipate,” “plan,” “expect,” “intend,” “estimate,” “project,” “may,” “will,” “should,” “would,” “could,” “can,” the negatives thereof, variations thereon and similar expressions, or by discussions of strategy, although not all forward-looking statements contain these words. Forward looking statements include, but are not limited to, (i) the successful closing and timing of the transaction with Map Labs, (ii) the anticipated synergies with respect to acquiring Map Labs, (iii) the anticipated revenue and EBIT from the transactions, (iv) the anticipated customer base from the transaction, (iv) the scale and profitability of the transaction, (v) the pathways to growth and margin expansion from the transaction, (vi) the form of funding for the transaction’s consideration, (vii) the use and adoption of Locafy’s products and solutions by partners and parties, (viii) the continued adoption of Locafy’s solutions in the US and other industries, continued revenue growth, and potential revenues generated from the adoption of Locafy’s solutions. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable, they do involve assumptions, risks, and uncertainties, and these expectations may prove to be incorrect. You should not place undue reliance on these

forward-looking statements, which speak only as of the date of this press release. The Company’s actual results could differ materially from those anticipated in these forward-looking statements as a result of a variety of factors, including those discussed in the Company’s filings with the Securities and Exchange Commission (the “SEC”), including the Company’s Annual Report on Form 20-F, filed with the SEC on November 12, 2025, as amended and restated, and available on its website(www.sec.gov). All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by these factors. Other than as required under the securities laws, the Company does not assume a duty to update these forward-looking statements.

Investor Relations Contact

Matt Glover
Gateway Group, Inc.
(949) 574-3860
LCFY@gateway-grp.com

Achieves key commercial project milestones utilizing its proprietary artificial intelligence (“AI”) and machine learning platform to identify and prioritize therapeutic targets

GAITHERSBURG, Md., Oct. 06, 2026 (GLOBE NEWSWIRE) — BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) (“BullFrog AI” or the “Company”), an AI company using its proprietary platform to turn complex biomedical data into actionable insights, announces it has achieved key project milestones under its commercial program with a top 5 global pharmaceutical company. BullFrog AI successfully identified and prioritized novel therapeutic targets for major depressive disorder (“MDD”) by applying its platform to proprietary neuropsychiatric multi-omic data sets.

“We’ve achieved important milestones and provided essential deliverables in our first commercial project with a global pharmaceutical company, identifying multiple novel and high-quality targets,” said BullFrog AI Founder and Chief Executive Officer Vin Singh. “We view this project as crucial commercial scale validation of our technology and believe our successes to date demonstrate the ability of our advanced AI and machine learning technologies to create high value assets.”

As a core component of its commercial strategy, BullFrog AI is also applying its technology to the discovery and development of novel drug targets for a range of other neuropsychiatric diseases, including schizophrenia and bipolar disorder. BullFrog AI believes there is significant opportunity to scale the application of its technology to other therapeutic areas of high patient impact through deep analysis of biomedical datasets.

About BullFrog AI        

BullFrog AI harnesses artificial intelligence and machine learning to advance pharmaceutical R&D and drug target discovery, providing AI-accelerated outputs that are optimized and human-validated. BullFrog AI operates through three complementary capabilities, deployable independently or as a combined platform: bfPREP^™ for biology-aware data harmonization, bfLEAP^® for causal AI analytics and patient subgroup discovery, and bfARENAS^™ for structured, auditable decision support. The common thread across all three: every output is traceable, every analytical decision is logged, and every recommendation is designed to be reviewed and validated by the scientific team before it drives a decision.

For more information visit BullFrog AI at: https://bullfrogai.com.

Safe Harbor Statement

This press release contains forward-looking statements. We base these forward-looking statements on our expectations and projections about future events, which we derive from the information currently available to us. Such forward-looking statements relate to future events or our future performance, including: our financial performance and projections; our revenue and earnings; and our business prospects and opportunities. You can identify forward-looking statements by those that are not historical in nature, particularly those that use terminology such as “may,” “should,” “could,” “will,” “expects,” “anticipates,” “contemplates,” “estimates,” “believes,” “plans,” “projected,” “predicts,” “potential,” or “hopes” or the negative of these or similar terms. In evaluating these forward-looking statements, you should consider various factors, including: our ability to change the direction of the Company; our ability to keep pace with new technology and changing market needs; our and our partners’ ability to market and sell our offerings and services; our ability to maintain compliance with Nasdaq listing rules; and the competitive environment of our business. These and other factors may cause our actual results to differ materially from any forward-looking statement. Forward-looking statements are only predictions. The forward-looking events discussed in this press release and other statements made from time to time by us or our representatives, may not occur, and actual events and results may differ materially and are subject to risks, uncertainties, and assumptions about us. We are not obligated to publicly update or revise any forward-looking statement, whether as a result of uncertainties and assumptions, the forward-looking events discussed in this press release and other statements made from time to time by us or our representatives might not occur.

Contact:

Investors:

CORE IR
ir@bullfrogai.com

Media:
pr@bullfrogai.com

Effort builds on prior collaboration to translate high-value use cases into practical applications running on IBM quantum computers

BOSTON, Oct. 06, 2026 (GLOBE NEWSWIRE) — Zapata Quantum (OTCQB: ZPTA) (“Zapata” or the “Company”) today announced it has joined the IBM Quantum Network with plans to use IBM’s world-class quantum computers with Zapata’s deep expertise in use-case discovery and application development. The Company’s effort aims to help close the quantum application gap by translating advances in quantum computing into mission-critical applications and real-world impact.

“The rapid progress IBM is making on the path to fault-tolerant quantum computing brings the quantum application gap into sharper focus,” said Sumit Kapur, CEO of Zapata Quantum. “These advances must be matched by progress in identifying, evaluating and developing the applications that will deliver real-world value. We are excited for Zapata’s Quantum Application Intelligence™ to translate organizations’ highest-mission priorities into practical quantum applications.”

“IBM’s roadmap to fault-tolerant quantum computing is one of the most credible in the industry, and superconducting qubits remain one of the most capable paths to advantage because their hardware is fast,” said Jonny Olson, VP Strategy and Co-Founder of Zapata Quantum. “Joining the IBM Quantum Network lets us better identify valuable opportunities for organizations that need the fastest systems, and then prepare those organizations for the precise moment that quantum gives them real ROI.”

Joining the IBM Quantum Network builds on a history of joint IBM and Zapata research done on early quantum devices. Zapata used IBM quantum computers in a landmark study published in Nature Biotechnology that produced experimentally validated candidates targeting KRAS and was selected as one of the journal’s Top 10 Articles of 2025.¹ Scientists from the two companies also co-authored research published in npj Quantum Information, which advanced the understanding of variational quantum factoring on a superconducting processor.²

Being part of the IBM Quantum Network also reflects Zapata’s broader strategy of working with technology leaders across the quantum and AI ecosystems. Insights from being part of the IBM Quantum Network will inform Quantum Pilot™, Zapata’s hardware-agnostic platform that helps enterprises identify, prioritize, and develop quantum applications as hardware matures.

To learn more about Zapata’s work in quantum application development, please visit the Company’s website.

1. Ghazi Vakili, M., Gorgulla, C., Snider, J. et al. Quantum-computing-enhanced algorithm unveils potential KRAS inhibitors. Nat Biotechnol 43, 1954–1959 (2025). https://doi.org/10.1038/s41587-024-02526-3
2. Karamlou, A.H., Simon, W.A., Katabarwa, A. et al. Analyzing the performance of variational quantum factoring on a superconducting quantum processor. npj Quantum Inf 7, 156 (2021). https://doi.org/10.1038/s41534-021-00478-z

About Zapata Quantum
Zapata Quantum is a leading hardware-agnostic, pure-play quantum software company focused on accelerating quantum application development. With a portfolio of more than 60 granted and pending patents developed over seven years, Zapata supports applications across cryptography, pharmaceuticals, finance, materials discovery, defense, and more. The Company is the only organization to have participated across all technical areas of DARPA’s Quantum Benchmarking program and has worked with Fortune 500 enterprises and government agencies to translate quantum advances into real-world impact. The Company’s study demonstrating the potential of quantum-enabled drug discovery was recognized as one of Nature Biotechnology’s Top 10 Papers of 2025. Learn more at zapataquantum.com.

Forward-Looking Statements

This press release contains forward-looking statements, including statements regarding the use of IBM’s quantum computers and the potential future applications and benefits of quantum applications and prospective opportunities and value that could be generated therefrom. Forward-looking statements may be prefaced by words such as “anticipate,” “expect,” “plan,” “could,” “may,” “will,” “should,” “would,” “intend,” “seem,” “potential,” “appear,” “continue,” “future,” “believe,” “estimate,” “forecast,” “project,” and similar words and expressions as they relate to us, are intended to identify forward-looking statements. Forward-looking statements are neither historical facts nor assurances of future performance, and are based on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict, many of which are outside of our control. We caution you, therefore, against relying on any of these forward-looking statements. Our actual results may differ materially from those contemplated by the forward-looking statements for a variety of reasons, including, without limitation, our ability to identify, develop and commercialize quantum computing technologies and practical applications for such technologies, our ability to secure and maintain contracts with customers and collaborators, the state of the U.S. economy including issues caused by affordability, the risk of future inflation and uncertainty surrounding interest rates and the possibility of a recession, uncertainty surrounding and impacts arising from tariffs and developments relating thereto, our ability to attract and retain key personnel, our ability to obtain, maintain and protect intellectual property rights, the risk that software and technology infrastructure on which we depend fails to perform as designed or intended, the possibility that competitors may develop or access technology with similar or superior capabilities to our technology offerings, the possibility of adverse regulatory developments that could adversely impact us or our collaborators or the technologies on which we depend, and the risk factors contained in our Annual Report on Form 10-K for the year ended December 31, 2025 filed with the Securities and Exchange Commission (the “SEC”) on March 31, 2026, and our Prospectus filed with the SEC on August 11, 2026. Any forward-looking statement made by us in this press release speaks only as of the date on which it is made. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by law. 

Media Contact
Taylor White
taylor@hkamarcom.com

Investor Relations Contact
Richard Land
investors@zapataquantum.com

Portage, Michigan, Oct. 06, 2026 (GLOBE NEWSWIRE) —

• Kevin Lobo to transition to Executive Chair of the Board of Directors
• Current President and COO Spencer Stiles appointed Chief Executive Officer
• Leadership transition effective January 1, 2027

Stryker (NYSE:SYK), a global leader in medical technologies, today announced that as part of a planned succession process, Kevin Lobo will transition to the role of Executive Chair of the Board of Directors, effective January 1, 2027. Spencer Stiles, currently President and Chief Operating Officer of Stryker, will succeed Lobo as Chief Executive Officer and will also be appointed as a member of the company’s Board at that time.

Lobo has led a distinguished career at Stryker spanning more than 15 years. He joined the company in 2011 as Group President, became Chief Executive Officer in October 2012 and was appointed Chair of the Board in July 2014. During his transformative 14-year tenure as CEO, Lobo significantly expanded Stryker’s portfolio and global presence and tripled annual net sales from $8.7 billion in 2012 to more than $26 billion in 2026. Under his leadership, Stryker has completed more than 60 acquisitions, including Mako, which combined pioneering robotic-arm-assisted technology with Stryker’s joint-reconstruction expertise to transform the orthopaedic industry, strengthening Stryker’s position as a diversified global leader in medical technologies. Lobo also helped shape the culture that defines Stryker today, establishing its mission to make healthcare better together with its customers, while advancing a specialized business operating model that has supported the company’s distinctive performance and growth.

“Serving as CEO of Stryker has been an incredible honor, and I am proud of all that our teams have accomplished together on behalf of our customers and the patients they serve,” said Lobo. “The Board and I have worked closely on a succession plan, and with our strong foundation in place, now is the right time for this leadership transition. Having worked alongside Spencer for many years, I have seen firsthand the qualities that define his leadership: his ability to set a clear direction, inspire people and translate strategy into strong execution. He understands what makes Stryker unique and has the judgment, experience and commitment to our mission and values to build on our momentum and lead the company forward. I look forward to working with Spencer to ensure a smooth transition and to continuing to support Stryker as Executive Chair of the Board.”

“I am honored to be named Stryker’s next CEO and grateful to the Board and Kevin for their trust in me,” said Stiles. “I have a deep appreciation for our people, our culture and the customer relationships that drive our innovation and growth. Kevin has built an extraordinary legacy and a strong foundation for the future, which I am excited to build upon as we continue executing our strategy, driving growth and advancing our mission to make healthcare better.”

Stiles is a strategic, growth-oriented and people-focused leader with a proven record of execution throughout his distinguished career at Stryker spanning nearly three decades. Since joining the company’s Endoscopy business in 1999, he has held leadership roles across nearly every Stryker business, spanning Orthopaedics, MedSurg and Neurotechnology. Before becoming President and Chief Operating Officer in January 2026, Stiles served as Group President, Orthopaedics, leading the company’s Joint Replacement and Trauma & Extremities businesses and its Digital, Robotics and Enabling Technologies organization, with additional responsibility for international regions and Stryker’s enterprise mergers and acquisitions strategy. He has also led significant portfolio initiatives, including the acquisition of Wright Medical, which enhanced Stryker’s global market position in trauma and extremities, and the separation of the company’s spinal implants business.

“This announcement is the culmination of a comprehensive, long-term succession planning process,” said Sheri McCoy, Lead Independent Director of Stryker’s Board of Directors. “Spencer is a proven leader with strategic perspective and the ability to unite teams around shared priorities. The Board is confident that he is the right leader to build upon Stryker’s momentum and guide the company’s next chapter. On behalf of the Board, I also want to recognize Kevin for his exceptional leadership and service over his tenure as CEO. Kevin has positioned Stryker to enter this transition from a place of strength. With a mission-driven culture, clear strategic direction and a strong leadership team, Stryker is poised to capture the significant opportunities ahead. We are fortunate that we will continue to benefit from his experience and perspectives as Executive Chair.”

Forward-Looking Statements
This press release contains forward-looking statements subject to the safe harbor protection provided by Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact are forward-looking statements, including statements regarding the Company’s strategy, growth prospects and opportunities, and the Company’s ability to execute on its priorities during and following the transition. These forward-looking statements involve various risks and uncertainties that could cause our actual results to differ materially from those expressed or implied in such statements. Such risks and uncertainties include, but are not limited to: risks associated with the transition of executive leadership and the ability of Mr. Stiles and the Company’s executive team to execute on the Company’s strategy and business plans; the Company’s ability to retain key personnel during and after the transition; and other risks listed or described from time to time in our filings with the U.S. Securities and Exchange Commission, including our Annual Report on Form 10-K and Quarterly Reports on Form 10-Q that we have filed or will file hereafter. We disclaim any intention or obligation to publicly update or revise any forward-looking statement to reflect any change in our expectations or in events, conditions or circumstances on which those expectations may be based, or that affect the likelihood that actual results will differ from those contained in the forward-looking statements, except to the extent required by law.

About Stryker
Stryker is a global leader in medical technologies and, together with our customers, we are driven to make healthcare better. We offer innovative products and services in MedSurg, Neurotechnology and Orthopaedics that help improve patient and healthcare outcomes. Alongside our customers around the world, we impact more than 150 million patients annually. More information is available at www.stryker.com.

Contacts
For investor inquiries:
Nick Mead, Vice President, Investor Relations at 269-385-2600 or nick.mead@stryker.com   

For media inquiries:
Kim Montagnino, Vice President, Chief Communications Officer at 269-385-2600 or kim.montagnino@stryker.com

Attachments

• Spencer Stiles Infographic
• Kevin Lobo Infographic

Naples, Italy and Hamilton, Bermuda, Oct. 06, 2026 (GLOBE NEWSWIRE) — The RoyaLand Company Ltd. (the “Company” or “RoyaLand”) (OTCQB: RLNDF), a Bermuda holding company focused on creating immersive, fantasy-based royalty-themed games as well as ownership and growth of its Italian professional football club Savoia 1908 FC (“Savoia” or the “Club”), today announced Savoia’s September performance, covering the Club’s league results, its run in the Coppa Italia (“Italian Cup”), and how the month fits into Savoia’s broader plan for the season.

The Club’s Plan: Build the Foundation Now, Grow From 2027/28

Savoia’s objective for the 2026/2027 season is to build the sporting and organizational foundations needed to establish itself in Serie C and then launch the Club’s growth program starting with the 2027/28 season. September was overall in line with expectations and offered positive signs of Savoia’s ability to compete at this level.

September in the League: Four Results Without Defeat

Following two defeats in the opening league matches played in August, Savoia’s squad responded by beating Altamura 2-0 in an away game and scoring three consecutive draws against Crotone, Foggia and Casarano. These four consecutive results without defeat kept the Club in the running for a competitive first season in Serie C. That run ended with a defeat later in the month.

Coppa Italia: A Statement Win in Catania

Another highlight of September was Savoia’s 3-0 away win against Catania in the Coppa Italia Serie C, which is an annual Italian domestic knock out competition played by 60 teams. This was a significant result at a prestigious venue that kept the Club’s run in the competition alive, following an earlier away win at Casertana. Savoia is now through to the Round of 16, with its next match set for October 28 against Sorrento. The Copa Italia Serie C winner qualifies for the promotion playoff round for potential advancement to Serie B.

Savoia’s 3-0 away victory over Catania marked a statement win and a place in the next round of the Coppa Italia Serie C.

About The RoyaLand Company Ltd.

The RoyaLand Company Ltd. is a Bermuda holding company focused on creating an online and offline immersive, fantasy-based royalty-themed game called TheRoyal.Land as well as mobile and other games, and ownership and growth of its Italian professional football club Savoia 1908 FC. The Company is actively focused on developing what it believes to be a novel, interactive and immersive game based on a player-empowered design. This game is expected to feature proprietary digital avatars and provide opportunities to players to earn in-game reward currency, build virtual land, and own their online assets while enhancing all of these features with premium incremental in-game content. Bridging the virtual video game world and terrestrial soccer, Savoia 1908 FC has also completed a tournament season for its eSports team competing in EA Sports FC™ online matches.

TheRoyal.Land and the management and development of Savoia 1908 FC are being conducted in collaboration with the Company’s founder and CEO Prince Emanuele Filiberto di Savoia — the grandson of the last King of Italy — as well as seven other royal families and families with legal, hereditary or historically based claims to royal positions in Russia, Albania, France, Bulgaria, Yugoslavia, Lesotho (Africa), and Mecklenburg (Germany). TheRoyal.Land is intended to integrate these families’ first-hand historical perspectives to deliver an authentic and unique past-meets-future entertainment experience.

CONTACT:
investors@theroyal.land
www.TheRoyal.Land

Attachment

• Savoia’s 3-0 away victory over Catania marked a statement win and a place in the next round of the Coppa Italia Serie C.

Tuesday, Oct. 27, 2026 at 4:30 p.m. Eastern Time

FREMONT, Calif., Oct. 06, 2026 (GLOBE NEWSWIRE) — Enphase Energy, Inc. (NASDAQ: ENPH), a global energy technology company, announced today that it will host a conference call and webcast on Tuesday, Oct. 27, 2026 at 4:30 p.m. Eastern Time to discuss its third quarter 2026 financial results for the period ended Sept. 30, 2026. The live webcast can be accessed on the Enphase Energy Investor Relations website at investor.enphase.com, and a recorded version of the call will also be available there approximately one hour after the call.

What:	Enphase Energy’s Third Quarter 2026 Financial Results Earnings Conference Call and Webcast
Date:	Tuesday, Oct. 27, 2026
Time:	4:30 p.m. Eastern Time
Live Call:	833.634.5018
International:	+1.412.902.4214
Replay:	United States/Canada: 855.669.9658
	International: +1.412.317.0088
	Replay access code: 5536681

About Enphase Energy, Inc.

Enphase Energy is a global energy technology company advancing intelligent power systems for homes, businesses, and next-generation AI data centers. The company designs semiconductor-based energy technologies spanning solar, batteries, EV charging, energy management, and virtual power plants, and is developing solid-state transformer technology to address the rapidly growing power demands of AI data centers. Based in Fremont, California, Enphase is the world’s leading supplier of microinverter-based solar and battery systems. The company revolutionized the solar industry with its microinverter technology and has shipped approximately 89.4 million microinverters, with approximately 5.3 million Enphase-based systems deployed in more than 165 countries. Enphase products enable people to harness the sun to make, use, save, and sell their own power, all controlled through the Enphase App. For more information, visit https://enphase.com/.

©2026 Enphase Energy, Inc. All rights reserved. Enphase Energy, Enphase, the “e” logo, IQ, and certain other marks listed at https://enphase.com/trademark-usage-guidelines are trademarks or service marks of Enphase Energy, Inc. Other names are for informational purposes and may be trademarks of their respective owners.

Contact:

Zach Freedman
Enphase Energy, Inc.
Investor Relations
ir@enphaseenergy.com

Veteran oncology leader to oversee nursing and laboratory services and advance clinical quality and professional development across the network

FORT MYERS, Fla., Oct. 06, 2026 (GLOBE NEWSWIRE) — American Oncology Network (AON), one of the nation’s fastest-growing networks of community oncology practices, today announced the promotion of Tena Messer to chief clinical officer.

In her new role, Messer provides strategic leadership for nursing and laboratory services across AON, with a focus on advancing clinical quality, strengthening professional development and building the infrastructure and resources that support clinical teams throughout the network.

“Tena, who has been an operations executive at AON for nearly seven years, has a deep understanding of community oncology and a strong commitment to supporting the clinicians who care for our patients every day,” said Todd Schonherz, chief executive officer of AON. “Her leadership will continue to be instrumental as we strengthen our clinical programs, invest in our teams and ensure our practices have the resources they need to deliver high-quality, patient-centered cancer care.”

As president of AON’s network operations, Ella Friedman works closely with the network’s clinical and operational leaders to strengthen practice performance and support the delivery of high-quality care across the network.

“Tena understands both the clinical realities of caring for patients and the operational support our teams need to do their best work,” Friedman said. “She is a thoughtful, collaborative leader who consistently keeps patients at the center of every decision. As AON continues to grow, her leadership remains critical to strengthening our clinical infrastructure while supporting the exceptional, personalized care our practices provide in their communities.”

A key priority for Messer is expanding professional development opportunities for AON’s nursing teams. Her work includes strengthening oncology education and onboarding while creating opportunities for continued learning as cancer treatments, technologies and care delivery models evolve.

Messer will also collaborate closely with AON’s Strategic Operations and Innovation Lab teams, led by Puneeth Indurlal, executive vice president of strategic operations and enterprise solutions, to identify opportunities to improve clinical workflows, optimize resources and reduce administrative burdens. Their work includes exploring how data, automation and artificial intelligence can better support clinicians and give them more time to focus on patient care.

“Tena and I share a common goal: making sure innovation translates into meaningful improvements for the people delivering care and the patients they serve,” Indurlal said. “By bringing together her clinical expertise with our work in strategic operations, data and technology, we can identify practical solutions that reduce unnecessary administrative work, improve workflows and help our clinical teams work more effectively.”

“Our nurses and clinical teams are at the heart of the care we provide,” Messer said. “I want to make sure they have the education, resources and tools they need to grow professionally and continue providing exceptional care. As oncology continues to evolve, we also have an opportunity to thoughtfully use technology and innovation to make their work easier and give them more time to focus on the reason they do what they do: their commitment to our patients.”

Messer brings 30 years of oncology experience to the role, including work as an oncology nurse and nurse practitioner in inpatient and outpatient settings. Throughout her career, she has led clinical quality initiatives, practice certifications and the development of outpatient programs focused on survivorship, oncology triage and palliative care.

Messer earned a Master of Science in nursing and an adult medicine nurse practitioner certificate with subspecialty training in oncology and HIV from Duke University School of Nursing. She also completed the Clinical Leadership Fellowship through CTI Leadership.

As chief clinical officer, Messer will work across AON to further connect clinical expertise, operational strategy and innovation while strengthening the clinical infrastructure that supports AON’s growing network of community oncology practices.

About American Oncology Network
American Oncology Network (AON) is an alliance of physicians and seasoned healthcare leaders partnering to ensure the long-term success and viability of community oncology and other specialties. Founded in 2018, AON’s rapidly expanding network represents more than 350 providers practicing across 21 states. AON pioneers innovative healthcare solutions through its physician-led model, fostering value-based care that improves patient outcomes while reducing costs and expanding access to quality care. AON equips its network physicians with the tools they need to thrive independently while providing comprehensive support, integrated revenue-diversifying ancillary services, and practice management expertise, enabling physicians to focus on what matters most – providing the highest standard of care for every patient. AON is committed to promoting health equity by addressing disparities in cancer care and ensuring that all patients have access to the care they need to achieve optimal health outcomes. With a focus on innovation and collaboration, AON is shaping the future of community oncology. For more information, please visit AONcology.com or follow us on LinkedIn, Facebook, X (formerly Twitter) and YouTube.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/6e40fa2e-a0d6-4716-a5b0-3b96b3017184

CONTACT: Media Contact:
Karen Riley Sawyer
American Oncology Network
Karen.Sawyer@AONcology.com

The competitive and esteemed award highlights Tri Pointe for fostering a welcoming workplace culture, expanding career pathways, and providing the support and development team members need to thrive

INCLINE VILLAGE, Nev., Oct. 06, 2026 (GLOBE NEWSWIRE) — Tri Pointe Homes^®, one of the largest homebuilders in the U.S., announced today that it has been selected for the 2026 Fortune Best Workplaces in Construction™ List by Great Place To Work^® and Fortune, marking the fifth consecutive year the company has earned the prestigious recognition. The distinction reflects Tri Pointe’s continued commitment to fostering a workplace where team members feel welcomed, supported, and empowered to grow while contributing to meaningful work across the homebuilding industry.

The Best Workplaces in Construction award is based on analysis of survey responses from more than 64,000 employees at Great Place To Work Certified™ companies in the construction industry. The highly competitive selection process celebrates companies that offer positive outcomes for their team members regardless of job role, race, gender, sexual orientation, or other demographic identifiers. Selection is based solely on employee feedback, providing a direct reflection of team members’ experiences within their workplace.

“Receiving this honor for a fifth consecutive year is a proud moment for Tri Pointe Homes because it’s the direct result of our team members, their experiences, and the company culture we strive to create,” said Heather Breidenthal, Chief Human Resources Officer of Tri Pointe Homes. “In 2026, 97% of team members said they felt welcomed when they joined the company, and 95% said they were made to feel right at home when changing jobs or work units. Those results speak to the culture our teams create every day and to our shared H.E.A.R.T. values of Humility, Empowerment, Authenticity, Results, and Team.”

Tri Pointe Homes continues to expand pathways into homebuilding and construction through college recruiting, internship programs, military recruitment partnerships, and its Cornerstone Club – a network of internal ambassadors who help guide and enhance recruiting, development, and mentoring efforts. Once hired, team members have access to resources designed to strengthen both professional development and connection across the company, including role-specific onboarding and learning programs that help new hires build the knowledge, relationships, and confidence needed to succeed.

The company also invests in opportunities for collaboration and development across disciplines and career stages. Initiatives such as its Area Construction Manager training program, National Safety Committee, and collaborative frame walks bring team members together to share expertise, reinforce quality and safety standards, strengthen field leadership and coaching capability, and align the cross-functional teams involved in delivering homes and communities.

The recognition among Fortune’s Best Workplaces in Construction™ list highlights Tri Pointe’s exceptional workplace culture within the construction industry. Great Place To Work, the global authority on workplace culture, determines its lists using its proprietary Trust Index™ Survey, which evaluates key factors including trust in management, connection with colleagues, and loyalty to the company. The companies that rank highest on this list are those where a broad set of employees across all demographics and roles report consistently positive workplace experiences. The highly competitive list is based on more than 1.3 million survey responses and data from companies representing more than 7.3 million employees. Honorees are selected based on their ability to provide consistently positive workplace experiences for employees across roles, work status, and demographic groups.

“A strong workplace culture is what makes great execution possible,” said Tri Pointe Homes President and Chief Operating Officer Tom Mitchell. “When people feel welcomed, supported, and trusted to do meaningful work, they bring more energy, ideas, and accountability to everything they do. That has a direct impact on how we collaborate, how we build, and ultimately, on the experience we create for our customers. Being recognized for a fifth consecutive year reinforces that investing in our people continues to be one of the most important investments we can make.”

Tri Pointe Homes continues to be a leader in fostering a workplace where team members can develop professionally, prioritize their wellbeing, and contribute to a shared sense of purpose. Through professional development, wellness resources, career pathways, community involvement, and a commitment to inclusion and belonging, the company works to create an environment in which team members feel supported and inspired throughout their careers.

For more information about Tri Pointe Homes and its award-winning culture, visit TriPointeHomes.com.

About Tri Pointe Homes^® 
One of the largest homebuilders in the U.S., Tri Pointe Homes, Inc. has a presence in 13 states and the District of Columbia, and is a recognized leader in customer experience, innovative design, and environmentally responsible business practices. The company builds premium homes and communities with deep ties to the communities it serves—some for as long as a century. Tri Pointe Homes combines the financial resources, technology platforms and proven leadership of a national organization with the regional insights, longstanding community connections and agility of empowered local teams. The company is one of the 2026 Fortune World’s Most Admired Companies, 2026 Fortune 100 Best Companies to Work For^®, and recognized as a PEOPLE Companies That Care^® (2023-2026) organization. The company was also named a Great Place To Work-Certified™ company for five years in a row and named on several Great Place To Work^® Best Workplaces lists. Tri Pointe has also won multiple Builder of the Year and Developer of the Year awards. For more information, visit TriPointeHomes.com.

About the Fortune Best Workplaces in Construction List
Great Place To Work selected the Fortune Best Workplaces in Construction by analyzing confidential survey responses from over 1.3 million employees, representing the experience of 7.3 million employees in the U.S. in 2025 and 2026. Of those responses, over 64,000 came from employees at Great Place To Work Certified companies in the construction industry, and these rankings are based on that feedback. Companies with 10 to 999 employees competed in the small and medium category. Companies with 1,000 or more employees were considered for the large category. Read the full methodology.
To get on this list next year, start here.

About Great Place To Work
As the global authority on workplace culture, Great Place To Work, a UKG company, brings 30 years of groundbreaking research and data to help every place become a great place to work for all. Its proprietary platform and Great Place To Work Model help companies evaluate the experience of every employee, with exemplary workplaces becoming Great Place To Work Certified and receiving recognition on a coveted Best Workplaces list.
Follow Great Place To Work on LinkedIn, X, and Instagram, and sign up for the Great Place To Work LinkedIn newsletter, Culture Edge, to get the latest research on what drives business success.

About Fortune Media
Fortune is a global multi-platform media company built on a legacy of trusted, award-winning reporting and information for those who want to make business better. Independently owned, Fortune tells the stories of the world’s biggest companies and their leaders as well as a new generation of innovators who are moving business forward. Digitally and in print, Fortune measures corporate performance through rigorous benchmarks, and holds companies accountable, in regions around the world. Its iconic rankings include Fortune 500, Fortune Global 500, Most Powerful Women, and World’s Most Admired Companies. Fortune builds world-class communities by convening industry thought leaders for exclusive summits and conferences, including the Fortune Global Forum, Fortune Brainstorm Tech, and Fortune Most Powerful Women. For more information, visit fortune.com.

Photos accompanying this announcement are available at:
https://www.globenewswire.com/NewsRoom/AttachmentNg/c0f5a407-ebf0-4901-b98b-682ac892eaad
https://www.globenewswire.com/NewsRoom/AttachmentNg/f3f1d3c7-6645-4284-bf39-1e35a20e139d

CONTACT: CONTACT:
Katy Biggerstaff
kbiggerstaff@newgroundco.com / 562.761.6338

TAIPEI, Taiwan, and BOTHELL, Wash., Oct. 06, 2026 (GLOBE NEWSWIRE) — YD Bio Limited (“YD Bio” or the “Company”) (Nasdaq: YDES), a biotechnology company advancing DNA methylation-based cancer detection technology and ophthalmologic innovations, today announced that the Company and EG BioMed Co., Ltd., a Taiwan registered company (“EG BioMed”), officially launched the AI Cancer Risk Assessment (the “Assessment”), an online assessment that organizes an individual’s self-reported health information into a personalized report in English and Chinese, covering ten cancer types with promotional pricing of US$10.

The Assessment is based on a 52-question health survey covering personal and family history, symptoms, lifestyle, environmental exposures and diet. The survey takes approximately ten minutes, with a personalized report generated shortly after completion. The report provides low, moderate or high risk stratification overall and for each of ten cancer types: breast, colorectal, lung, head and neck, pancreatic, liver, endometrial, prostate, biliary tract and gastric cancer. It identifies the factors that contributed most to each result, explains why they may be relevant, and includes screening information and personalized follow-up guidance. The Assessment requires no blood draw, imaging or a clinic visit.

Assessment Methodology and Report

Responses are processed by a 48-feature pan-cancer model and ten cancer-specific models, together with a separate rule layer built from published clinical literature. This rule layer draws on more than 140 primary research studies and over 300 traceable risk estimates, with each rule tied to a source study and reported measure. The report includes the rules triggered by the user’s responses, their bases and references to the underlying medical literature.

Results are presented against the population baseline of the country the respondent selects, using age-standardized incidence rates. The accompanying screening information also reflects guidance issued by a particular country, as applicable (currently, the United States, Canada and Taiwan). Where a country has no national recommendation for a given cancer, the report says so rather than substituting another country’s advice.

Integration with the Companies’ Oncology Services

The Assessment sits upstream of the companies’ laboratory and clinical services. EG BioMed US Inc. (“EG BioMed US”) operates a CLIA-certified and CAP-accredited laboratory in Bothell, Washington, offering DNA methylation–based oncology tests as laboratory-developed tests. Its operational footprint spans 47 U.S. states, Washington, D.C., Guam, the U.S. Virgin Islands and American Samoa. In March 2026, YD Bio and EG BioMed launched a nationwide telehealth platform to support decentralized access to such services.

For individuals whose Assessment indicates a denser cluster of risk factors associated with certain cancer types, the report may reference the availability of related blood tests for discussion with a physician. Whether any test is appropriate remains a decision for a licensed physician.

“Understanding personal health risk factors can be a useful starting point for more informed discussions with healthcare professionals,” said Dr. Ethan Shen, Founder, Chairman and Chief Executive Officer of YD Bio. “This Assessment brings self-reported health information and published research together in a structured, personalized report. As part of our broader oncology platform, we believe it can help individuals better understand their risk factors and discuss appropriate next steps with their physicians.”

The AI Cancer Risk Assessment is available now in English and Chinese at mdi.eg-bio.com/product/ai-cancer-risk-assessment. During the promotional period, the Assessment is offered at US$10, reduced from its regular price of US$50.

Important Disclosure about the Assessment

The AI Cancer Risk Assessment is a cancer risk-stratification and health guidance tool. It uses statistical and artificial intelligence methods applied to health information self-reported by the user. Its output does not represent the probability of developing cancer. It does not diagnose cancer and is not intended for cancer diagnosis, screening, early detection, disease prediction or treatment decision-making; it cannot replace professional medical evaluation, diagnostic testing or consultation with a qualified healthcare provider.

About EG BioMed

EG BioMed is a biotechnology and clinical services company focused on advancing early cancer detection and diagnostic solutions. YD Bio entered into a Memorandum of Understanding to merge with EG BioMed in January 2026 and is advancing the transaction, which is anticipated to close in 2026, subject to customary closing conditions, regulatory approvals, and the finalization of definitive agreements.

EG BioMed US is the U.S. clinical-laboratory subsidiary of EG BioMed and operates a CLIA-certified, CAP-accredited clinical laboratory in Bothell, Washington, focused on DNA methylation–based early cancer detection and AI-driven biomarker analytics. EG BioMed and EG BioMed US are affiliates of YD Bio.

About YD Bio Limited

YD Bio is a U.S.-anchored public biotechnology company building an integrated healthcare platform spanning regulated molecular diagnostics, clinical services, precision medicine, and life science commercialization. The Company operates DNA methylation–based oncology testing programs in the United States under a laboratory-developed test strategy and supports pharmaceutical and biotechnology partners through compliant life science distribution and clinical trial supply chain services. In addition, the Company maintains regulated ocular health commercialization operations and a consumer health distribution platform in Asia. For more information, visit ir.ydesgroup.com and follow the Company on Facebook, X, Threads, Instagram and LinkedIn.

Forward-looking statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are intended to be covered by the safe harbor provisions created by the U.S. Private Securities Litigation Reform Act of 1995, including statements regarding the Company’s plans, objectives and expectations for its business, strategy, operations, and certain on-going transactions, and the potential benefit of the Assessment and any synergies with its other oncology services. Forward-looking statements are not guarantees of future performance and can be identified by words such as “aim,” “intend,” “seek,” “believe,” “designed to,” “expects,” “anticipates,” “plans,” “may,” “could,” “will” and other similar expressions. Actual results may differ materially from those expressed or implied due to a variety of factors, including consumer demand and market acceptance; competition; regulatory and labeling requirements in Taiwan and other jurisdictions; currency exchange rates; geopolitical tensions and macroeconomic conditions; and other risks and uncertainties described in YD Bio’s filings with the U.S. Securities and Exchange Commission. The Company cautions investors not to place undue reliance on such forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to update any forward-looking statement, except as required by law, and encourages investors to review the risk factors in its Annual Report on Form 20-F and other SEC filings.

For investor and media inquiries, please contact:
YD Bio Limited
Investor Relations
Email: investor@ydesgroup.com

WFS Investor Relations Inc.
Email: services@wfsir.com
Phone: +1 628 283 9214